Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Valeant Pharma Sees Bausch & Lomb Acquisition as China Entry

publication date: May 29, 2013
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Valeant Pharma, Canada’s largest drugmaker, announced yesterday it would pay $8.7 billion to acquire Bausch & Lomb. With the transaction, Valeant bought a substantial portfolio of eye care products, but it also acquired, for the first time, a sales foothold in China. Valeant said it would leverage B&L’s China organization to bring its own products to the PRC. More details....

Stock Symbol: (NYSE: VRX)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...